JP2006526630A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006526630A5 JP2006526630A5 JP2006514164A JP2006514164A JP2006526630A5 JP 2006526630 A5 JP2006526630 A5 JP 2006526630A5 JP 2006514164 A JP2006514164 A JP 2006514164A JP 2006514164 A JP2006514164 A JP 2006514164A JP 2006526630 A5 JP2006526630 A5 JP 2006526630A5
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- naphthyl
- methoxyphenyl
- cyano
- carbon atoms
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000004204 2-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C([H])=C1[H] 0.000 claims 40
- 125000004432 carbon atom Chemical group C* 0.000 claims 37
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 claims 17
- 229910052739 hydrogen Inorganic materials 0.000 claims 17
- 239000001257 hydrogen Substances 0.000 claims 17
- 125000000217 alkyl group Chemical group 0.000 claims 16
- 150000001875 compounds Chemical class 0.000 claims 15
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 14
- 125000001325 propanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 claims 13
- PHRABVHYUHIYGY-UHFFFAOYSA-N 1-methylnaphthalene Chemical group C1=CC=C2C([CH2])=CC=CC2=C1 PHRABVHYUHIYGY-UHFFFAOYSA-N 0.000 claims 12
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 11
- -1 2,5-dimethoxyphenyl Chemical group 0.000 claims 10
- 125000003118 aryl group Chemical group 0.000 claims 10
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 9
- 150000002431 hydrogen Chemical class 0.000 claims 8
- 150000003839 salts Chemical class 0.000 claims 8
- 229910052717 sulfur Inorganic materials 0.000 claims 8
- 238000000034 method Methods 0.000 claims 6
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims 6
- 229910052757 nitrogen Inorganic materials 0.000 claims 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 5
- KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 claims 4
- 125000003545 alkoxy group Chemical group 0.000 claims 4
- 125000003710 aryl alkyl group Chemical group 0.000 claims 4
- 125000000753 cycloalkyl group Chemical group 0.000 claims 4
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical group C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 claims 4
- 229910052736 halogen Inorganic materials 0.000 claims 4
- 150000002367 halogens Chemical class 0.000 claims 4
- 125000004414 alkyl thio group Chemical group 0.000 claims 3
- 125000004093 cyano group Chemical group *C#N 0.000 claims 3
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 3
- 125000004001 thioalkyl group Chemical group 0.000 claims 3
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims 2
- 235000010290 biphenyl Nutrition 0.000 claims 2
- KMPWYEUPVWOPIM-KODHJQJWSA-N cinchonidine Chemical compound C1=CC=C2C([C@H]([C@H]3[N@]4CC[C@H]([C@H](C4)C=C)C3)O)=CC=NC2=C1 KMPWYEUPVWOPIM-KODHJQJWSA-N 0.000 claims 2
- KMPWYEUPVWOPIM-UHFFFAOYSA-N cinchonidine Natural products C1=CC=C2C(C(C3N4CCC(C(C4)C=C)C3)O)=CC=NC2=C1 KMPWYEUPVWOPIM-UHFFFAOYSA-N 0.000 claims 2
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 claims 2
- 125000004985 dialkyl amino alkyl group Chemical group 0.000 claims 2
- 125000004990 dihydroxyalkyl group Chemical group 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 229960002179 ephedrine Drugs 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims 2
- IVXQBCUBSIPQGU-UHFFFAOYSA-N piperazine-1-carboxamide Chemical compound NC(=O)N1CCNCC1 IVXQBCUBSIPQGU-UHFFFAOYSA-N 0.000 claims 2
- LOUPRKONTZGTKE-LHHVKLHASA-N quinidine Chemical class C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@H]2[C@@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-LHHVKLHASA-N 0.000 claims 2
- YQLLYZBVSCXIAA-VTIYRKAUSA-N (2r)-2-[(r)-(2-methoxyphenyl)-naphthalen-1-ylmethyl]-2-methyl-3-[4-(2-methylphenyl)piperazin-1-yl]-3-oxopropanenitrile Chemical compound COC1=CC=CC=C1[C@H]([C@](C)(C#N)C(=O)N1CCN(CC1)C=1C(=CC=CC=1)C)C1=CC=CC2=CC=CC=C12 YQLLYZBVSCXIAA-VTIYRKAUSA-N 0.000 claims 1
- RPFNBMZGDHKJOY-PUDHBBIYSA-N (2s)-2-[(s)-(2-methoxyphenyl)-naphthalen-1-ylmethyl]-2-methyl-3-(4-naphthalen-1-ylpiperazin-1-yl)-3-oxopropanenitrile Chemical compound COC1=CC=CC=C1[C@@H]([C@@](C)(C#N)C(=O)N1CCN(CC1)C=1C2=CC=CC=C2C=CC=1)C1=CC=CC2=CC=CC=C12 RPFNBMZGDHKJOY-PUDHBBIYSA-N 0.000 claims 1
- MEONWHRRZKGBQZ-CQTOTRCISA-N (2s)-2-[(s)-(2-methoxyphenyl)-naphthalen-1-ylmethyl]-2-methyl-3-[4-(3-methylphenyl)piperazin-1-yl]-3-oxopropanenitrile Chemical compound COC1=CC=CC=C1[C@@H]([C@@](C)(C#N)C(=O)N1CCN(CC1)C=1C=C(C)C=CC=1)C1=CC=CC2=CC=CC=C12 MEONWHRRZKGBQZ-CQTOTRCISA-N 0.000 claims 1
- UZQJLNXFWLULHK-CQTOTRCISA-N (2s)-2-[(s)-(2-methoxyphenyl)-naphthalen-1-ylmethyl]-2-methyl-3-oxo-3-[4-[3-(trifluoromethyl)phenyl]-3,6-dihydro-2h-pyridin-1-yl]propanenitrile Chemical compound COC1=CC=CC=C1[C@@H]([C@@](C)(C#N)C(=O)N1CC=C(CC1)C=1C=C(C=CC=1)C(F)(F)F)C1=CC=CC2=CC=CC=C12 UZQJLNXFWLULHK-CQTOTRCISA-N 0.000 claims 1
- JZPONCMNBSEYQW-CQTOTRCISA-N (2s)-2-[(s)-(2-methoxyphenyl)-naphthalen-1-ylmethyl]-2-methyl-3-oxo-3-[4-[3-(trifluoromethyl)phenyl]piperidin-1-yl]propanenitrile Chemical compound COC1=CC=CC=C1[C@@H]([C@@](C)(C#N)C(=O)N1CCC(CC1)C=1C=C(C=CC=1)C(F)(F)F)C1=CC=CC2=CC=CC=C12 JZPONCMNBSEYQW-CQTOTRCISA-N 0.000 claims 1
- VSXGKDDHXRHELA-CQTOTRCISA-N (2s)-2-[(s)-(2-methoxyphenyl)-naphthalen-1-ylmethyl]-3-[4-(3-methoxyphenyl)piperazin-1-yl]-2-methyl-3-oxopropanenitrile Chemical compound COC1=CC=CC(N2CCN(CC2)C(=O)[C@](C)(C#N)[C@H](C=2C(=CC=CC=2)OC)C=2C3=CC=CC=C3C=CC=2)=C1 VSXGKDDHXRHELA-CQTOTRCISA-N 0.000 claims 1
- QGLQWMMQAAFGGN-UZNNEEJFSA-N (2s,3s)-2-[4-(1h-indol-4-yl)piperazine-1-carbonyl]-3-(2-methoxyphenyl)-2-methyl-3-naphthalen-1-ylpropanenitrile Chemical compound COC1=CC=CC=C1[C@@H]([C@@](C)(C#N)C(=O)N1CCN(CC1)C=1C=2C=CNC=2C=CC=1)C1=CC=CC2=CC=CC=C12 QGLQWMMQAAFGGN-UZNNEEJFSA-N 0.000 claims 1
- DCCPNFFQPPRMAK-BHDXBOSCSA-N (2s,3s)-2-[4-(2,3-dichlorophenyl)piperazine-1-carbonyl]-3-(2-methoxyphenyl)-2-methyl-3-naphthalen-1-ylpropanenitrile Chemical compound COC1=CC=CC=C1[C@@H]([C@@](C)(C#N)C(=O)N1CCN(CC1)C=1C(=C(Cl)C=CC=1)Cl)C1=CC=CC2=CC=CC=C12 DCCPNFFQPPRMAK-BHDXBOSCSA-N 0.000 claims 1
- ZUEWWCPREOHWEN-QWOOXDRHSA-N (2s,3s)-2-[4-(2,3-dihydro-1h-inden-4-yl)piperazine-1-carbonyl]-3-(2-methoxyphenyl)-2-methyl-3-naphthalen-1-ylpropanenitrile Chemical compound COC1=CC=CC=C1[C@@H]([C@@](C)(C#N)C(=O)N1CCN(CC1)C=1C=2CCCC=2C=CC=1)C1=CC=CC2=CC=CC=C12 ZUEWWCPREOHWEN-QWOOXDRHSA-N 0.000 claims 1
- SSHPWBDOIDZSCP-UZNNEEJFSA-N (2s,3s)-2-[4-(2,3-dimethylphenyl)piperazine-1-carbonyl]-3-(2-methoxyphenyl)-2-methyl-3-naphthalen-1-ylpropanenitrile Chemical compound COC1=CC=CC=C1[C@@H]([C@@](C)(C#N)C(=O)N1CCN(CC1)C=1C(=C(C)C=CC=1)C)C1=CC=CC2=CC=CC=C12 SSHPWBDOIDZSCP-UZNNEEJFSA-N 0.000 claims 1
- DUAHHJADGMHDAK-XDFJSJKPSA-N (2s,3s)-2-[4-(2-chlorophenyl)piperazine-1-carbonyl]-3-(2-methoxyphenyl)-2-methyl-3-naphthalen-1-ylpropanenitrile Chemical compound COC1=CC=CC=C1[C@@H]([C@@](C)(C#N)C(=O)N1CCN(CC1)C=1C(=CC=CC=1)Cl)C1=CC=CC2=CC=CC=C12 DUAHHJADGMHDAK-XDFJSJKPSA-N 0.000 claims 1
- YDPHVMLWKVJBQE-XDFJSJKPSA-N (2s,3s)-2-[4-(2-fluorophenyl)piperazine-1-carbonyl]-3-(2-methoxyphenyl)-2-methyl-3-naphthalen-1-ylpropanenitrile Chemical compound COC1=CC=CC=C1[C@@H]([C@@](C)(C#N)C(=O)N1CCN(CC1)C=1C(=CC=CC=1)F)C1=CC=CC2=CC=CC=C12 YDPHVMLWKVJBQE-XDFJSJKPSA-N 0.000 claims 1
- JKPJSOHGSKFXIK-UZNNEEJFSA-N (2s,3s)-2-[4-(3,4-dimethylphenyl)piperazine-1-carbonyl]-3-(2-methoxyphenyl)-2-methyl-3-naphthalen-1-ylpropanenitrile Chemical compound COC1=CC=CC=C1[C@@H]([C@@](C)(C#N)C(=O)N1CCN(CC1)C=1C=C(C)C(C)=CC=1)C1=CC=CC2=CC=CC=C12 JKPJSOHGSKFXIK-UZNNEEJFSA-N 0.000 claims 1
- RDYVLJXNUNCGGT-UZNNEEJFSA-N (2s,3s)-2-[4-(3,5-dimethoxyphenyl)piperazine-1-carbonyl]-3-(2-methoxyphenyl)-2-methyl-3-naphthalen-1-ylpropanenitrile Chemical compound COC1=CC(OC)=CC(N2CCN(CC2)C(=O)[C@](C)(C#N)[C@H](C=2C(=CC=CC=2)OC)C=2C3=CC=CC=C3C=CC=2)=C1 RDYVLJXNUNCGGT-UZNNEEJFSA-N 0.000 claims 1
- LUIUWFWPBAGLHR-XDFJSJKPSA-N (2s,3s)-2-[4-(3-chlorophenyl)piperazine-1-carbonyl]-3-(2-methoxyphenyl)-2-methyl-3-naphthalen-1-ylpropanenitrile Chemical compound COC1=CC=CC=C1[C@@H]([C@@](C)(C#N)C(=O)N1CCN(CC1)C=1C=C(Cl)C=CC=1)C1=CC=CC2=CC=CC=C12 LUIUWFWPBAGLHR-XDFJSJKPSA-N 0.000 claims 1
- ITWQRJZKAATYDR-CQTOTRCISA-N (2s,3s)-2-[4-(4-chlorophenyl)-3,6-dihydro-2h-pyridine-1-carbonyl]-3-(2-methoxyphenyl)-2-methyl-3-naphthalen-1-ylpropanenitrile Chemical compound COC1=CC=CC=C1[C@@H]([C@@](C)(C#N)C(=O)N1CC=C(CC1)C=1C=CC(Cl)=CC=1)C1=CC=CC2=CC=CC=C12 ITWQRJZKAATYDR-CQTOTRCISA-N 0.000 claims 1
- NEYGOQHEACXZQW-XDFJSJKPSA-N (2s,3s)-2-[4-(4-chlorophenyl)piperazine-1-carbonyl]-3-(2-methoxyphenyl)-2-methyl-3-naphthalen-1-ylpropanenitrile Chemical compound COC1=CC=CC=C1[C@@H]([C@@](C)(C#N)C(=O)N1CCN(CC1)C=1C=CC(Cl)=CC=1)C1=CC=CC2=CC=CC=C12 NEYGOQHEACXZQW-XDFJSJKPSA-N 0.000 claims 1
- UBVIGVSCRZJWOE-CQTOTRCISA-N (2s,3s)-2-[4-[4-chloro-3-(trifluoromethyl)phenyl]-3,6-dihydro-2h-pyridine-1-carbonyl]-3-(2-methoxyphenyl)-2-methyl-3-naphthalen-1-ylpropanenitrile Chemical compound COC1=CC=CC=C1[C@@H]([C@@](C)(C#N)C(=O)N1CC=C(CC1)C=1C=C(C(Cl)=CC=1)C(F)(F)F)C1=CC=CC2=CC=CC=C12 UBVIGVSCRZJWOE-CQTOTRCISA-N 0.000 claims 1
- QLYQQJLNIFDUNH-CQTOTRCISA-N (2s,3s)-2-[4-[4-chloro-3-(trifluoromethyl)phenyl]piperidine-1-carbonyl]-3-(2-methoxyphenyl)-2-methyl-3-naphthalen-1-ylpropanenitrile Chemical compound COC1=CC=CC=C1[C@@H]([C@@](C)(C#N)C(=O)N1CCC(CC1)C=1C=C(C(Cl)=CC=1)C(F)(F)F)C1=CC=CC2=CC=CC=C12 QLYQQJLNIFDUNH-CQTOTRCISA-N 0.000 claims 1
- PYUXCEVGIQTTRI-UHFFFAOYSA-N 2-[4-(3-chloro-2-methylphenyl)piperazine-1-carbonyl]-3-(2-methoxyphenyl)-2-methyl-3-naphthalen-1-ylpropanenitrile Chemical compound COC1=CC=CC=C1C(C(C)(C#N)C(=O)N1CCN(CC1)C=1C(=C(Cl)C=CC=1)C)C1=CC=CC2=CC=CC=C12 PYUXCEVGIQTTRI-UHFFFAOYSA-N 0.000 claims 1
- KMUGNMLSZIAXRC-UHFFFAOYSA-N 2-[4-(4-chlorophenyl)piperidine-1-carbonyl]-3-(2-methoxyphenyl)-2-methyl-3-naphthalen-1-ylpropanenitrile Chemical compound COC1=CC=CC=C1C(C(C)(C#N)C(=O)N1CCC(CC1)C=1C=CC(Cl)=CC=1)C1=CC=CC2=CC=CC=C12 KMUGNMLSZIAXRC-UHFFFAOYSA-N 0.000 claims 1
- 125000006280 2-bromobenzyl group Chemical group [H]C1=C([H])C(Br)=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 125000006276 2-bromophenyl group Chemical group [H]C1=C([H])C(Br)=C(*)C([H])=C1[H] 0.000 claims 1
- HTWKSMOAZUVCLC-UHFFFAOYSA-N 2-cyano-2-methyl-3-naphthalen-1-yl-3-[2-(trifluoromethyl)phenyl]propanoic acid Chemical compound C=1C=CC2=CC=CC=C2C=1C(C(C#N)(C)C(O)=O)C1=CC=CC=C1C(F)(F)F HTWKSMOAZUVCLC-UHFFFAOYSA-N 0.000 claims 1
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 claims 1
- 125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 229940100198 alkylating agent Drugs 0.000 claims 1
- 239000002168 alkylating agent Substances 0.000 claims 1
- 230000002152 alkylating effect Effects 0.000 claims 1
- 150000001412 amines Chemical class 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 125000005127 aryl alkoxy alkyl group Chemical group 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 125000004981 cycloalkylmethyl group Chemical group 0.000 claims 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- CNKCDDUMEAKBMY-UHFFFAOYSA-N ethyl 2-cyano-3-(2,4-dimethoxyphenyl)-3-naphthalen-1-ylpropanoate Chemical compound C=1C=CC2=CC=CC=C2C=1C(C(C#N)C(=O)OCC)C1=CC=C(OC)C=C1OC CNKCDDUMEAKBMY-UHFFFAOYSA-N 0.000 claims 1
- HAWZLUYUKKDNQT-UHFFFAOYSA-N ethyl 2-cyano-3-(2,6-dichlorophenyl)-3-naphthalen-1-ylpropanoate Chemical compound C=1C=CC2=CC=CC=C2C=1C(C(C#N)C(=O)OCC)C1=C(Cl)C=CC=C1Cl HAWZLUYUKKDNQT-UHFFFAOYSA-N 0.000 claims 1
- FTSXTKLDGMGCEN-UHFFFAOYSA-N ethyl 2-cyano-3-(2,6-dimethoxyphenyl)-3-naphthalen-1-ylpropanoate Chemical compound C=1C=CC2=CC=CC=C2C=1C(C(C#N)C(=O)OCC)C1=C(OC)C=CC=C1OC FTSXTKLDGMGCEN-UHFFFAOYSA-N 0.000 claims 1
- BCMHUBAKWXCWES-UHFFFAOYSA-N ethyl 2-cyano-3-(2-methoxyphenyl)-3-naphthalen-1-ylpropanoate Chemical compound C=1C=CC2=CC=CC=C2C=1C(C(C#N)C(=O)OCC)C1=CC=CC=C1OC BCMHUBAKWXCWES-UHFFFAOYSA-N 0.000 claims 1
- XEJUPNISYVEWOR-UHFFFAOYSA-N ethyl 2-cyano-3-naphthalen-1-yl-3-(2-propan-2-ylphenyl)propanoate Chemical compound C=1C=CC2=CC=CC=C2C=1C(C(C#N)C(=O)OCC)C1=CC=CC=C1C(C)C XEJUPNISYVEWOR-UHFFFAOYSA-N 0.000 claims 1
- QSQIOLZIBXSXMS-UHFFFAOYSA-N ethyl 2-cyano-3-naphthalen-1-yl-3-[2-(trifluoromethyl)phenyl]propanoate Chemical compound C=1C=CC2=CC=CC=C2C=1C(C(C#N)C(=O)OCC)C1=CC=CC=C1C(F)(F)F QSQIOLZIBXSXMS-UHFFFAOYSA-N 0.000 claims 1
- 150000004820 halides Chemical class 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 230000003301 hydrolyzing effect Effects 0.000 claims 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- PJFPVGFPENNCND-KPKJPENVSA-N methyl (e)-2-cyano-3-quinolin-3-ylprop-2-enoate Chemical compound C1=CC=CC2=CC(/C=C(C(=O)OC)\C#N)=CN=C21 PJFPVGFPENNCND-KPKJPENVSA-N 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 125000001624 naphthyl group Chemical group 0.000 claims 1
- 125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- FVSKHRXBFJPNKK-UHFFFAOYSA-N propionitrile Chemical compound CCC#N FVSKHRXBFJPNKK-UHFFFAOYSA-N 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 125000006413 ring segment Chemical group 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- NOFLSPNCSWNKMK-UHFFFAOYSA-N tert-butyl 2-cyano-3-(2,6-dimethylphenyl)-3-naphthalen-1-ylpropanoate Chemical compound CC1=CC=CC(C)=C1C(C(C#N)C(=O)OC(C)(C)C)C1=CC=CC2=CC=CC=C12 NOFLSPNCSWNKMK-UHFFFAOYSA-N 0.000 claims 1
- FNNBTMYOIIUTFI-UHFFFAOYSA-N tert-butyl 2-cyano-3-(2-methoxyphenyl)-3-naphthalen-1-ylpropanoate Chemical compound COC1=CC=CC=C1C(C(C#N)C(=O)OC(C)(C)C)C1=CC=CC2=CC=CC=C12 FNNBTMYOIIUTFI-UHFFFAOYSA-N 0.000 claims 1
- IYZKSQINJIJKKF-UHFFFAOYSA-N tert-butyl 2-cyano-3-naphthalen-1-yl-3-(2-propan-2-ylphenyl)propanoate Chemical compound CC(C)C1=CC=CC=C1C(C(C#N)C(=O)OC(C)(C)C)C1=CC=CC2=CC=CC=C12 IYZKSQINJIJKKF-UHFFFAOYSA-N 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
- MUDSDYNRBDKLGK-UHFFFAOYSA-N Cc1ccnc2ccccc12 Chemical compound Cc1ccnc2ccccc12 MUDSDYNRBDKLGK-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US46656703P | 2003-04-30 | 2003-04-30 | |
| US10/833,678 US20050004164A1 (en) | 2003-04-30 | 2004-04-28 | 2-Cyanopropanoic acid amide and ester derivatives and methods of their use |
| PCT/US2004/013360 WO2004099150A2 (en) | 2003-04-30 | 2004-04-30 | 3-(1-naphthyl)-2-cyanopropanoic acid derivatives as estrogen receptor ligands |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006526630A JP2006526630A (ja) | 2006-11-24 |
| JP2006526630A5 true JP2006526630A5 (enExample) | 2007-06-07 |
Family
ID=33436706
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006514164A Pending JP2006526630A (ja) | 2003-04-30 | 2004-04-30 | ２−シアノプロパン酸アミドおよびエステル誘導体ならびにそれらの使用法。 |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US20050004164A1 (enExample) |
| EP (1) | EP1620102B1 (enExample) |
| JP (1) | JP2006526630A (enExample) |
| KR (1) | KR20060015556A (enExample) |
| AR (1) | AR044762A1 (enExample) |
| AT (1) | ATE418335T1 (enExample) |
| AU (1) | AU2004236216A1 (enExample) |
| BR (1) | BRPI0409921A (enExample) |
| CA (1) | CA2523235A1 (enExample) |
| CO (1) | CO5700755A2 (enExample) |
| CR (1) | CR8041A (enExample) |
| DE (1) | DE602004018629D1 (enExample) |
| MX (1) | MXPA05011581A (enExample) |
| NO (1) | NO20054969L (enExample) |
| RU (1) | RU2005137175A (enExample) |
| TW (1) | TW200508217A (enExample) |
| WO (1) | WO2004099150A2 (enExample) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9904723D0 (sv) | 1999-12-22 | 1999-12-22 | Carlsson A Research Ab | New modulators of dopamine neurotransmission II |
| USRE46117E1 (en) | 1999-12-22 | 2016-08-23 | Teva Pharmaceuticals International Gmbh | Modulators of dopamine neurotransmission |
| SE9904724D0 (sv) | 1999-12-22 | 1999-12-22 | Carlsson A Research Ab | New modulators of dopamine neurotransmission I |
| US7544350B2 (en) | 2002-11-22 | 2009-06-09 | Hallstar Innovations Corp. | Method of decreasing the UV light degradation of polymers |
| DK1773772T3 (da) * | 2004-06-08 | 2010-09-13 | Nsab Af Neurosearch Sweden Ab | Nye disubstituerede phenylpiperidiner/piperaziner som modulatorer af dopaminneurotransmission |
| US7851629B2 (en) | 2004-06-08 | 2010-12-14 | Nsab, Filial Af Neurosearch Sweden Ab, Sverige | Disubstituted phenylpiperidines as modulators of dopamine and serotonin neurotransmission |
| KR101245075B1 (ko) | 2004-06-08 | 2013-03-18 | 엔에스아베 필리알 아프 뉴로서치 스웨덴 아베 스베리게 | 도파민 신경전달의 모듈레이터로서 신 2기치환된페닐피페리딘/피페라진 |
| US7476752B2 (en) | 2004-06-14 | 2009-01-13 | Wyeth | Processes for the preparation of 2-cyano-3-naphthalene-1-yl-3-phenyl-propionic acid alkyl or benzyl esters |
| EP2248524A3 (en) | 2004-08-25 | 2011-03-09 | Takeda Pharmaceutical Company Limited | Preventives/remedies for stress urinary incontinence and method of screening the same |
| CA2584831C (en) | 2004-10-13 | 2013-09-17 | Neurosearch Sweden Ab | Process for the synthesis of 4-(3-methanesulfonylphenyl)-1-n-propyl-piperidine |
| CN100562514C (zh) * | 2005-07-22 | 2009-11-25 | 中国科学院上海药物研究所 | 一类取代丙酰胺衍生物、其制备方法和用途 |
| SE529246C2 (sv) | 2005-10-13 | 2007-06-12 | Neurosearch Sweden Ab | Nya disubstituerade fenyl-piperidiner som modulatorer för dopaminneurotransmission |
| RU2303597C1 (ru) * | 2006-05-12 | 2007-07-27 | Иващенко Андрей Александрович | Фармацевтическая композиция, способы ее получения и применения |
| WO2007132841A1 (ja) | 2006-05-16 | 2007-11-22 | Takeda Pharmaceutical Company Limited | 縮合複素環化合物およびその用途 |
| EP2089355A2 (en) * | 2006-11-01 | 2009-08-19 | Brystol-Myers Squibb Company | Modulators of glucocorticoid receptor, ap-1, and/or nf- kappa b activity and use thereof |
| JP5520051B2 (ja) | 2007-11-15 | 2014-06-11 | 武田薬品工業株式会社 | 縮合ピリジン誘導体およびその用途 |
| WO2011071136A1 (ja) | 2009-12-11 | 2011-06-16 | アステラス製薬株式会社 | 線維筋痛症治療剤 |
| WO2011094426A1 (en) | 2010-01-29 | 2011-08-04 | The United State Of America, As Represented By The Secretary, Department Of Health & Human Services | Caspase inhibitors |
| PT3002008T (pt) * | 2010-03-11 | 2018-12-24 | Univ New York | Compostos de amido como moduladores roryt e suas utilizações |
| JP2014528933A (ja) * | 2011-09-09 | 2014-10-30 | ニューヨーク ユニバーシティ | ＲＯＲγｔモジュレーターとしてのアミド化合物およびその使用 |
| UY34503A (es) | 2011-12-08 | 2013-07-31 | Ivax Int Gmbh | ?sal de bromhidrato de pridopidina? |
| JP6177875B2 (ja) | 2012-04-04 | 2017-08-09 | テバ・ファーマシューティカルズ・インターナショナル・ゲーエムベーハーＴｅｖａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｔｅｒｎａｔｉｏｎａｌ ＧｍｂＨ | 併用療法のための医薬組成物 |
| EP2855651B1 (de) | 2012-05-30 | 2016-11-02 | Clariant International Ltd | N-methyl-n-acylglucamin enthaltende zusammensetzung |
| BR112014029759A2 (pt) | 2012-05-30 | 2017-06-27 | Clariant Finance Bvi Ltd | uso de n-metil-n-acilglucaminas como solubilizadores |
| DE102012021647A1 (de) | 2012-11-03 | 2014-05-08 | Clariant International Ltd. | Wässrige Adjuvant-Zusammensetzungen |
| LT3004090T (lt) | 2013-05-28 | 2018-01-10 | Astrazeneca Ab | Cheminiai junginiai |
| DE202014008418U1 (de) | 2014-02-19 | 2014-11-14 | Clariant International Ltd. | Schaumarme agrochemische Zusammensetzungen |
| DE102014005771A1 (de) | 2014-04-23 | 2015-10-29 | Clariant International Ltd. | Verwendung von wässrigen driftreduzierenden Zusammensetzungen |
| DE202015008045U1 (de) | 2015-10-09 | 2015-12-09 | Clariant International Ltd. | Universelle Pigmentdispersionen auf Basis von N-Alkylglukaminen |
| DE102015219651A1 (de) | 2015-10-09 | 2017-04-13 | Clariant International Ltd. | Zusammensetzungen enthaltend Zuckeramin und Fettsäure |
| DE102016207877A1 (de) | 2016-05-09 | 2017-11-09 | Clariant International Ltd | Stabilisatoren für Silikatfarben |
| KR101828241B1 (ko) * | 2016-10-17 | 2018-02-13 | (주)네오팜 | 항염용 조성물 |
| KR101828240B1 (ko) | 2016-10-17 | 2018-02-13 | (주)네오팜 | 항염용 조성물 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6451817B1 (en) * | 1995-03-10 | 2002-09-17 | Eli Lilly And Company | Alpha-substituted-1-benzyl-napthyls |
| CA2262906C (en) * | 1996-08-12 | 2006-10-31 | Celgene Corporation | Novel immunotherapeutic agents and their use in the reduction of cytokine levels |
| JP2001511814A (ja) * | 1997-02-15 | 2001-08-14 | プロスクリプト・インコーポレイテッド | ＮＦ−κＢの阻害を介する梗塞の治療 |
| DE69830218T2 (de) * | 1997-08-07 | 2006-02-02 | Eli Lilly And Co., Indianapolis | 1-[4-Substituierte Alkoxy)benzylnaphthalinderivate als Östrogeninhibitoren |
| JPH11295383A (ja) * | 1998-04-15 | 1999-10-29 | Mitsubishi Electric Corp | マイクロ波帯域用半導体トランジスタのバーンイン方法、バーンイン装置及びバーンインした半導体装置 |
| HUP0102782A3 (en) * | 1998-06-19 | 2002-12-28 | Smithkline Beecham Corp | Salycilanilide as inhibitors of transcription factor nf-kb |
| HRP20010944B1 (hr) * | 1999-06-23 | 2010-08-31 | Sanofi-Aventis Deutschland Gmbh | Supstituirani benzimidazoli |
| DE19951360A1 (de) * | 1999-10-26 | 2001-05-03 | Aventis Pharma Gmbh | Substituierte Indole |
| AU2003278955A1 (en) * | 2003-09-24 | 2005-05-11 | Wyeth | METHOD OF TREATING RHEUMATOID ARTHRITIS USING NF-kB INHIBITORS |
| AU2003272675A1 (en) * | 2003-09-24 | 2005-05-11 | Wyeth | Use of estrogen receptor ligands for the treatment of inflammatory bowel disease |
| AU2003272676A1 (en) * | 2003-09-24 | 2005-05-11 | Wyeth | METHODS OF TREATING ATHEROSCLEROSIS USING NF-kB INHIBITORS |
-
2004
- 2004-04-28 US US10/833,678 patent/US20050004164A1/en not_active Abandoned
- 2004-04-29 TW TW093111996A patent/TW200508217A/zh unknown
- 2004-04-30 AT AT04750987T patent/ATE418335T1/de not_active IP Right Cessation
- 2004-04-30 AR ARP040101492A patent/AR044762A1/es unknown
- 2004-04-30 EP EP04750987A patent/EP1620102B1/en not_active Expired - Lifetime
- 2004-04-30 KR KR1020057020599A patent/KR20060015556A/ko not_active Withdrawn
- 2004-04-30 DE DE602004018629T patent/DE602004018629D1/de not_active Expired - Fee Related
- 2004-04-30 CA CA002523235A patent/CA2523235A1/en not_active Abandoned
- 2004-04-30 JP JP2006514164A patent/JP2006526630A/ja active Pending
- 2004-04-30 AU AU2004236216A patent/AU2004236216A1/en not_active Abandoned
- 2004-04-30 BR BRPI0409921-4A patent/BRPI0409921A/pt not_active IP Right Cessation
- 2004-04-30 MX MXPA05011581A patent/MXPA05011581A/es not_active Application Discontinuation
- 2004-04-30 WO PCT/US2004/013360 patent/WO2004099150A2/en not_active Ceased
- 2004-04-30 RU RU2005137175/04A patent/RU2005137175A/ru not_active Application Discontinuation
-
2005
- 2005-10-12 CR CR8041A patent/CR8041A/es not_active Application Discontinuation
- 2005-10-26 CO CO05109228A patent/CO5700755A2/es not_active Application Discontinuation
- 2005-10-26 NO NO20054969A patent/NO20054969L/no not_active Application Discontinuation
-
2007
- 2007-07-31 US US11/831,375 patent/US20070299105A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006526630A5 (enExample) | ||
| RU2005137175A (ru) | Производные сложного эфира и амида 2-цианопропановой кислоты и способы их применения | |
| CN100347162C (zh) | N－苯基－2－嘧啶胺衍生物 | |
| JP2011504485A5 (enExample) | ||
| JP2022043059A5 (enExample) | ||
| TW555735B (en) | Diarylpropylamines, methods for their preparation and pharmaceutical compositions containing them | |
| JP2020506171A5 (enExample) | ||
| RU2010120682A (ru) | Ингибиторы гистондезацетилазы | |
| JP3862301B2 (ja) | ３級アミンの製造方法 | |
| JP2007526336A5 (enExample) | ||
| HUP0302966A2 (hu) | Karboxamid-vegyületek és alkalmazásuk humán 11CBY receptor antagonistákként, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények | |
| HUT55348A (en) | Process n-phenyl-alkyl-substituted alpha-aminocarboxamide derivatives and pharmaceutical compositions comprising same | |
| JP2005522438A5 (enExample) | ||
| CS246080B2 (en) | Method of piperazine derivatives production | |
| RU2005134686A (ru) | Пиримидиновые соединения | |
| CN1646500A (zh) | 芳基取代的嘧啶及其用途 | |
| JP2007509116A5 (enExample) | ||
| JP2004525951A5 (enExample) | ||
| CN1396905A (zh) | 不对称合成(s)－(+)－3－(氨甲基)－5－甲基己酸 | |
| MX2007002911A (es) | Derivados de anilina sustituidos. | |
| CA2321198A1 (en) | 2-arylethyl-(piperidin-4-ylmethyl)amine derivatives as muscarinic receptor antagonists | |
| JP2004533450A5 (enExample) | ||
| RU2005111968A (ru) | Производные 4-пирролидинофенилбензилового эфира | |
| RU2008143232A (ru) | Новый класс ингибиторов гистондеацетилаз | |
| SK14852000A3 (sk) | Kalcilytické zlúčeniny, farmaceutický prostriedok s ich obsahom a ich použitie |